Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Signoretti

Showing results (191-200 of 257) with videos related to

Pageof 26
Sort By:
Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
Nature Metabolism|February 6, 2025
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinomaJiao Li, Kaimeng Huang, Meha Thakur, et al.
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Nature Genetics|January 17, 2018
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerMing Chen, Jiangwen Zhang, Katia Sampieri, et al.
Nature Genetics|October 22, 2025
Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerMing Chen, Jiangwen Zhang, Katia Sampieri, et al.
The Oncologist|June 27, 2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following ImmunotherapyJustine Panian, Ava Saidian, Kevin Hakimi, et al.
Cancer Cell|April 5, 2024
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomesRenée Maria Saliby, Chris Labaki, Tejas R Jammihal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Developmental Cell|August 27, 2025
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancerDeli Hong, Ying Lyu, Richa Nayak, et al.
Pageof 26

Showing results (191-200 of 257) with videos related to

Sort By:
Pageof 26
Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
Nature Metabolism|February 6, 2025
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinomaJiao Li, Kaimeng Huang, Meha Thakur, et al.
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Nature Genetics|January 17, 2018
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerMing Chen, Jiangwen Zhang, Katia Sampieri, et al.
Nature Genetics|October 22, 2025
Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerMing Chen, Jiangwen Zhang, Katia Sampieri, et al.
The Oncologist|June 27, 2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following ImmunotherapyJustine Panian, Ava Saidian, Kevin Hakimi, et al.
Cancer Cell|April 5, 2024
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomesRenée Maria Saliby, Chris Labaki, Tejas R Jammihal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Developmental Cell|August 27, 2025
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancerDeli Hong, Ying Lyu, Richa Nayak, et al.
Pageof 26